Pharmion Corporation Announces FDA Acceptance of Vidaza NDA Supplement for IV Administration for Filing and Grants Six (PR Newswire via Yahoo! Finance)
Pharmion Corporation today announced that the U.S. Food and Drug Administration accepted for filing and established a six month review goal for the Company's new drug application supplement to add IV administration to instructions in the prescribing information for its demethylating agent Vidaza .

Pharmion Corporation Announces FDA Acceptance Of Vidaza NDA Supplement For IV Administration For Filing And Grants Six (Medical News Today)
Pharmion Corporation(Nasdaq: PHRM) today announced that the U.S. Food and Drug Administration(FDA) accepted for filing and established a six month review goal for theCompany's new drug application (NDA) supplement to add IV administration toinstructions in the prescribing information for its demethylating agentVidaza(R) (azacitidine for injectable suspension). [click link for full article]

FDA Grants Fast Track Status to MyVax(R) Personalized Immunotherapy for Follicular Non-Hodgkin's Lymphoma (RedNova)
REDWOOD CITY, Calif., June 13 /PRNewswire-FirstCall/ -- Genitope Corporation today announced that MyVax(R) personalized immunotherapy received Fast Track designation from the U.S. Food & Drug Administration (FDA) for the treatment of follicular non-Hodgkin's Lymphoma (fNHL).